

August 8, 2025

To, <b>BSE Limited,</b> 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Ref:</b> Company Scrip Code: 532834	To, Listing Department, <b>National Stock Exchange of India Ltd.,</b> Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 <b>Ref:</b> Symbol: CAMLINFINE    Series: EQ
--	---

**Sub: Outcome of the Board Meeting: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time (“Listing Regulations”) (read with Schedule III).**

Dear Sir/Madam,

This has reference to our intimation dated August 1, 2025.

This is to inform you that the Board of Directors, at its meeting held today i.e. on Friday, August 8, 2025, inter alia, approved the following:

- a) Un-audited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2025. A copy of the said Results along with the Limited Review Reports issued by the Statutory Auditors are enclosed herewith as Annexure 1. The same are also being uploaded on the Company’s Website (<https://www.camlinfs.com/>). The said Results shall be published in newspapers as per the Listing Regulations.
- b) Based on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the Shareholders of the Company, the Board has approved the re-appointment of Mr. Joseph Conrad D’Souza (DIN: 00010576) as a Non-Executive Independent Director of the Company, not liable to retire by rotation for a second term of five consecutive years for the period from September 29, 2025 to September 28, 2030;
- c) Notice of Postal Ballot for the re-appointment of Mr. Joseph Conrad D’Souza as a Non-Executive Independent Director for a second term of 5 (five) consecutive years.
- d) Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Hari Rajmohan (DIN: 11228394) to act as an Alternate Director to Mr. Jens Van Nieuwenborgh (DIN: 07638244), Non-Executive Non-Independent Director of the Company during the latter's absence on August 8, 2025.
- e) Interim ad hoc charge of the Human Resources & Administration Department given to Mr. Santosh Parab, Chief Financial Officer of the Company pursuant to the resignation of Mr. Amarsinh Jadhavrao, Chief Executive (HR & Corporate Affairs), and until a suitable successor is appointed. Although Mr. Santosh Parab has not been directly responsible for the Human Resources & Administration function, he has consistently provided valuable advice to the Managing Director in this area over the years. As a result, he has acquired sufficient experience to competently assume this role.



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

Disclosure under Regulation 30 read with Schedule III of Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure 2.

The above information is also available on the Company's Website (<https://www.camlinfs.com/>).

The Board meeting commenced at 01:30 p.m. (IST) and concluded at 03:35 p.m. (IST).

This is for your information and record please.

Encl.: a/a.

Thanking You,

**For Camlin Fine Sciences Limited**

**Rahul Sawale**  
**Company Secretary**  
**& VP - Legal**



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

CAMLIN FINE SCIENCES LIMITED  
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2025

(Rs. in Lakh, except per share data)

	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
		30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
1	Revenue from operations	19,143.82	27,259.63	18,191.22	88,649.13	42,355.20	43,746.28	38,085.20	166,652.66
2	Other income	368.87	893.66	178.01	2,061.53	856.34	959.25	186.76	1,445.26
3	<b>Total income</b>	<b>19,512.69</b>	<b>28,153.29</b>	<b>18,369.23</b>	<b>90,710.66</b>	<b>43,211.54</b>	<b>44,705.53</b>	<b>38,271.96</b>	<b>168,097.92</b>
4	<b>Expenses</b>								
	Cost of materials consumed	9,906.06	15,002.87	13,169.71	53,922.47	22,585.48	19,486.59	21,454.27	78,626.18
	Purchase of stock in trade	47.10	58.24	226.12	1,695.32	1,741.34	236.13	1,584.26	11,753.19
	Changes in inventories of finished goods/WIP/stock in trade	294.97	(326.07)	(3,196.39)	(7,491.39)	(638.76)	1,807.02	(2,626.99)	(5,453.54)
	Employee benefits expense	1,862.07	1,889.00	1,681.32	7,248.10	5,957.00	5,012.67	4,625.75	19,229.13
	Finance costs	1,134.39	1,743.93	1,361.73	6,611.93	1,582.70	1,610.99	2,327.23	9,988.22
	Depreciation and amortisation expense	1,340.32	1,313.48	1,269.32	5,252.66	1,692.03	1,838.62	1,454.79	6,383.89
	Other expenses	6,565.43	7,308.61	5,617.11	26,214.41	10,807.24	11,263.14	10,157.80	41,686.45
	<b>Total Expenses</b>	<b>21,150.34</b>	<b>26,990.06</b>	<b>20,128.92</b>	<b>93,453.50</b>	<b>43,727.03</b>	<b>41,255.16</b>	<b>38,977.11</b>	<b>162,213.52</b>
5	<b>Profit / (Loss) before exceptional items and share of profit / (loss) of associate (3-4)</b>	<b>(1,637.65)</b>	<b>1,163.23</b>	<b>(1,759.69)</b>	<b>(2,742.84)</b>	<b>(515.49)</b>	<b>3,450.37</b>	<b>(705.15)</b>	<b>5,884.40</b>
6	<b>Exceptional items</b>	-	(26.45)	-	9,600.21	-	559.40	-	981.52
7	<b>Profit / (Loss) before share of profit / (loss) of associate (5-6)</b>	<b>(1,637.65)</b>	<b>1,189.68</b>	<b>(1,759.69)</b>	<b>(12,343.05)</b>	<b>(515.49)</b>	<b>2,890.97</b>	<b>(705.15)</b>	<b>4,902.88</b>
8	<b>Share of profit / (loss) of associate</b>	-	-	-	-	89.07	178.61	-	44.22
9	<b>Profit / (Loss) before tax from continuing operations (7-8)</b>	<b>(1,637.65)</b>	<b>1,189.68</b>	<b>(1,759.69)</b>	<b>(12,343.05)</b>	<b>(426.42)</b>	<b>3,069.58</b>	<b>(705.15)</b>	<b>4,947.10</b>
10	<b>Tax Expenses</b>								
	- Current tax	-	-	(378.28)	165.97	597.59	1,399.17	739.88	4,212.81
	- Deferred tax	(569.55)	(372.16)	(13.40)	(4,877.97)	(598.59)	(603.97)	377.08	(4,206.16)
	<b>Total Tax Expenses</b>	<b>(569.55)</b>	<b>(372.16)</b>	<b>(391.68)</b>	<b>(4,712.00)</b>	<b>(1.00)</b>	<b>795.20</b>	<b>1,116.96</b>	<b>6.65</b>
11	<b>Profit / (Loss) from continuing operations for the period (9-10)</b>	<b>(1,068.10)</b>	<b>1,561.84</b>	<b>(1,368.01)</b>	<b>(7,631.05)</b>	<b>(425.42)</b>	<b>2,274.38</b>	<b>(1,822.11)</b>	<b>4,940.45</b>
12	<b>Discontinued operations</b>								
	Profit / (Loss) from discontinued operation before tax	-	-	-	-	(642.69)	(2,263.38)	(1,642.91)	(20,752.39)
	Tax expense of discontinued operations	-	-	-	-	-	-	-	-
	<b>Profit / (Loss) from discontinued operations</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(642.69)</b>	<b>(2,263.38)</b>	<b>(1,642.91)</b>	<b>(20,752.39)</b>
13	<b>Profit / (Loss) for the period</b>	<b>(1,068.10)</b>	<b>1,561.84</b>	<b>(1,368.01)</b>	<b>(7,631.05)</b>	<b>(1,068.11)</b>	<b>11.00</b>	<b>(3,465.02)</b>	<b>(15,811.94)</b>
14	<b>Other comprehensive income</b>								
A	<b>Items that will not be reclassified to profit or loss</b>								
(i)	Remeasurements of defined benefit plans	15.55	18.50	(15.57)	(12.26)	15.55	18.96	(15.57)	(11.80)
(ii)	Income tax relating to Items that will not be reclassified to profit or loss	(5.43)	(6.47)	5.44	4.28	(5.43)	(6.47)	5.44	4.28
B	<b>Items that will be reclassified to profit or loss</b>								
(i)	Exchange differences on translating the financial statements of foreign operations	-	-	-	-	1,170.39	384.70	(650.17)	(1,169.91)
(ii)	The effective portion of gain or loss on hedging instruments in a cash flow hedge	18.98	280.18	100.58	(70.81)	18.98	280.18	100.58	(70.81)
(iii)	Income tax relating to Items that will be reclassified to profit or loss	(6.63)	(97.90)	(35.15)	24.75	(6.63)	(97.90)	(35.15)	24.75
	<b>Other comprehensive income</b>	<b>22.47</b>	<b>194.31</b>	<b>55.30</b>	<b>(54.04)</b>	<b>1,192.86</b>	<b>579.47</b>	<b>(594.87)</b>	<b>(1,223.49)</b>
15	<b>Total comprehensive income for the period (13+14)</b>	<b>(1,045.63)</b>	<b>1,756.15</b>	<b>(1,312.71)</b>	<b>(7,685.09)</b>	<b>124.75</b>	<b>590.47</b>	<b>(4,059.89)</b>	<b>(17,035.43)</b>



	PARTICULARS	STANDALONE				CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
		30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
		(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
16	<b>Profit / (Loss) attributable to:</b>								
	(i) Owners of the Company					(996.07)	(72.40)	(3,395.41)	(13,904.59)
	(ii) Non-controlling interests					(72.04)	83.40	(69.61)	(1,907.35)
	<b>Profit attributable to owners arises from:</b>								
	Continuing operations					(405.81)	2,136.14	(1,900.20)	5,000.16
	Discontinued operations					(590.26)	(2,208.54)	(1,495.21)	(18,904.75)
17	<b>Other comprehensive income attributable to:</b>								
	(i) Owners of the Company					1,190.63	513.16	(645.93)	(1,224.42)
	(ii) Non-controlling interests					2.23	66.31	51.06	0.93
18	<b>Total comprehensive income attributable to:</b>								
	(i) Owners of the Company					194.56	440.76	(4,041.34)	(15,129.01)
	(ii) Non-controlling interests					(69.81)	149.71	(18.55)	(1,906.42)
	<b>Total comprehensive income attributable to owners arises from:</b>								
	Continuing operations					784.82	2,649.30	(2,546.13)	3,775.74
	Discontinued operations					(590.26)	(2,208.54)	(1,495.21)	(18,904.75)
19	Paid-up Equity Share Capital (Face Value Rs.1/- per share)	1,879.21	1,879.21	1,674.95	1,879.21	1,879.21	1,879.21	1,674.95	1,879.21
20	Other Equity				84,347.71				88,288.09
	Earnings per Share (EPS) for profit from continuing operation (of Re 1/- each) (not annualised) (Refer Note 5)								
	Basic (Rs.)					(0.22)	1.17	(1.12)	2.89
	Diluted (Rs.)					(0.21)	1.16	(1.11)	2.86
	Earnings per Share (EPS) for profit from from discontinued operation (of Re 1/-each) (not annualised) (Refer Note 5)								
	Basic (Rs.)					(0.31)	(1.21)	(0.88)	(10.92)
	Diluted (Rs.)					(0.31)	(1.20)	(0.87)	(10.80)
21	Earnings per Share (EPS) for profit from continuing and discontinued operation (of Re 1/-each) (not annualised) (Refer Note 5)								
	Basic (Rs.)	(0.57)	0.86	(0.80)	(4.41)	(0.53)	(0.04)	(1.99)	(8.03)
	Diluted (Rs.)	(0.56)	0.85	(0.80)	(4.36)	(0.52)	(0.04)	(1.98)	(7.95)

**Notes to Standalone and Consolidated Unaudited Financial Results:**

- The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on August 8, 2025. The financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, and other accounting principles generally accepted in India.
- The figures for the quarter ended March 31, 2025 as reported in these results are the balancing figures between audited figures in respect of the year ended March 31, 2025 and the published year to date figures up to the end of the third quarter of the relevant financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- Other income / Other expense above relating to continuing operations includes net foreign exchange gain / (loss) for each reporting period as under:

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	61.15	-	15.83	678.52	614.44	577.83	-	154.77
Exchange loss	-	54.55	-	-	-	-	1,027.25	-
<b>Total Exchange gain / (loss)</b>	<b>61.15</b>	<b>(54.55)</b>	<b>15.83</b>	<b>678.52</b>	<b>614.44</b>	<b>577.83</b>	<b>(1,027.25)</b>	<b>154.77</b>

The exchange gain / (loss) shown above excludes exchange gain / (loss) on derivative contracts accounted as cash flow hedge.



4 Finance costs of continuing operation include foreign exchange gain / (loss) for each reporting period as under:

Rs. In Lakh

Particulars	STANDALONE				CONSOLIDATED			
	QUARTER ENDED			YEAR ENDED	QUARTER ENDED			YEAR ENDED
	30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)	(Unaudited)	(Audited) (Refer Note 2)	(Unaudited)	(Audited)
Exchange gain	10.27	21.82	-	-	-	573.21	-	-
Exchange loss	-	-	20.04	543.12	92.54	-	636.94	2,370.50
<b>Total Exchange gain / (loss)</b>	<b>10.27</b>	<b>21.82</b>	<b>(20.04)</b>	<b>(543.12)</b>	<b>(92.54)</b>	<b>573.21</b>	<b>(636.94)</b>	<b>(2,370.50)</b>

5 On November 22, 2024, the Board of Directors of the Company, approved the right issue of equity shares for an amount upto Rs. 2,25,00,00,000/-. Pursuant to it, the Securities Issue and Allotment Committee of the Board at its meeting held on January 8, 2025 declared a right issue of 2,04,26,244 equity shares of Re 1 each for a subscription of Rs. 110 per share (Including a share premium of Rs. 109 per equity share) aggregating to Rs. 2,24,68,86,840/- for a right entitlement of 5 right equity shares for 41 equity shares held.

The Securities Issue and Allotment Committee of the Board at its meeting held on January 31, 2025, took on record the Basis of Allotment and approved the allotment of 2,04,25,805 Right Equity Shares to successful applicants for a total amount of Rs. 2,24,68,38,550. The aforesaid allotment does not include the entitlements of 439 Rights Equity Shares which have been kept in abeyance. Basic and Diluted EPS are recalculated to give effect of the right issue in all reporting periods in accordance with IND AS 33 (Earnings Per Share)

6 During the quarter ended June 30, 2025, the Company has neither issued nor allotted any shares under any Employees Stock Option Scheme. Under ESOP-2018, 8,875 employee stock options have lapsed which have been added back to the option pool and are eligible for re-issue.

7 The operations of the Cash Generating Units relating to the Diphenol facility of CFS Europe SPA, Italy (a wholly owned subsidiary), and the Vanillin manufacturing facility of CFS Wanglong Flavors (Ningbo) Co. Ltd., China (a subsidiary), had ceased manufacturing activities with effect from August 16, 2023, and February 19, 2021, respectively. As previously disclosed, the Board of Directors, at its meeting held on November 11, 2024, had determined that both operations were economically unviable. Accordingly, impairments relating to the investments and assets of these subsidiaries were recognized in the standalone and consolidated financial results for the quarter ended September 30, 2024, and classified as Exceptional Items.

In line with this assessment, and as concluded in the quarter ended March 31, 2025, with remote prospects of revival, these operations continue to be classified as discontinued operations in the current quarter's financial results, as well as for all prior periods presented, in accordance with IND AS 105 (Non-current Assets Held for Sale and Discontinued Operations).

8 The Company's operations constitute a single business segment in Speciality Chemicals.

Place: Mumbai  
Date: August 8, 2025

For Camlin Fine Sciences Limited

  
Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379



# KALYANIWALLA & MISTRY LLP


CHARTERED ACCOUNTANTS

## REVIEW REPORT TO THE BOARD OF DIRECTORS CAMLIN FINE SCIENCES LIMITED

- 1) We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Camlin Fine Sciences Limited** ("the Company") for the quarter ended June 30, 2025, together with the notes thereon, ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations") duly initialled by us for identification. This Statement, which is the responsibility of the Company's Management, has been reviewed by the Audit Committee and approved by the Board of Directors, at their respective meetings held on August 08, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under Section 133 of the Companies Act, 2013, ("the Act") read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
- 2) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- 4) Other Matter:  
Attention is drawn to the fact that the figures for the quarter ended March 31, 2025, as reported in these financial results are the balancing figures between audited figures in respect of the full financial year ended March 31, 2025, and published unaudited year to date figures up to the third quarter of the year ended March 31, 2025, which have been reviewed and not subject to audit by us.

Our conclusion on the Statement is not modified in respect of the above matter.

For **Kalyaniwalla & Mistry LLP**  
Chartered Accountants  
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni  
Partner  
Membership No.: 047576  
UDIN: 25047576BMKXLL5380  
Place: Mumbai  
Date: August 08, 2025



# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

## REVIEW REPORT TO THE BOARD OF DIRECTORS CAMLIN FINE SCIENCES LIMITED

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Camlin Fine Sciences Limited ("the Parent" ), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") and its share of net profit after tax and total comprehensive income of an associate of a step down subsidiary (refer paragraph 3 below) for the quarter ended June 30, 2025 together with the notes thereon ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, ("the Listing Regulations") duly initialled by us for identification. This Statement, which is the responsibility of the Parent's Management has been reviewed by the Parent's Audit Committee and approved by the Parent's Board of Directors at their respective meetings held on August 8, 2025, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 - Interim Financial Reporting ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 2) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 3) The Statement includes the results of the following subsidiaries / step down subsidiaries / associate:

### Incorporated In India

Sr. No.	Name of the Entity	Relationship
I	Chemolutions Chemicals Ltd.	Subsidiary
Ii	AlgalR Nutra Pharms Private Limited	Subsidiary

### Incorporated Outside India

Sr. No.	Name of the Entity	Relationship
i.	CFS North America LLC	Wholly owned subsidiary
ii.	CFS Do Brasil Indústria, Comércio, Importação e Exportação De Aditivos Alimentícios LTDA	Wholly owned subsidiary
iii.	Solentus North America Inc	Wholly owned subsidiary
iv.	CFS Europe S.P.A	Wholly owned subsidiary



<b>Sr. No.</b>	<b>Name of the Entity</b>	<b>Relationship</b>
v.	Dresen Quimica S.A.P.I de C.V.	Wholly owned subsidiary
vi.	Industrias Petrotec De Mexico S.A. de C.V.	Step down subsidiary
vii.	Nuvel, S.A.C.	Step down subsidiary
viii.	Britec, S.A.	Step down subsidiary
ix.	Inovel, S.A.S	Step down subsidiary
x.	Grinel, S.R.L	Step down subsidiary
xi.	CFS Wanglong Flavors (Ningbo) Co. Ltd.	Subsidiary
xii.	CFS Pahang Asia Pte. Ltd.	Subsidiary
xiii.	CFS Argentina S.A.	Step down subsidiary
xiv.	CFS Chile De SPA	Step down subsidiary
xv.	CFS PP (M) SDN. BHD	Subsidiary
xvi.	Vitafor Invest NV, Belgium	Step down subsidiary
xvii.	Vitafor NV,	Step down subsidiary
xviii.	Addi-Tech NV	Step down subsidiary
xix.	Vitafor China Ltd.	Step down subsidiary
xx.	Vial SARL	Associate of a step down subsidiary

4) Based on our review conducted and procedures performed as stated in paragraph 2 above and based on the consideration of the review reports of the other auditors referred to in paragraph 5(A) below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

5) Other Matters:

A. We did not review the interim financial results of 14 subsidiaries incorporated outside India and 2 subsidiaries in India included in the Statement, whose interim financial results reflect Group's share of total revenues (before consolidation adjustments) of Rs. 30,825.86 Lakh, Group's share of total net profit after tax (before consolidation adjustments) of Rs. 3.44 Lakh and total comprehensive income (before consolidation adjustments) of Rs. 2,359.74 Lakh for the quarter ended June 30, 2025.

The Statement also includes the Group's share of net profit after tax and total comprehensive income (before consolidation adjustments) of Rs. 89.07 Lakh for the quarter ended June 30, 2025, as considered in the consolidated unaudited financial results, in respect of an associate of a step down subsidiary, located outside India.

These interim financial results of the subsidiaries and an associate of a step down subsidiary as mentioned in this paragraph have been reviewed by other auditors whose reports have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and an associate of a step down subsidiary, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 2 above.



In respect of these subsidiaries and an associate of a step down subsidiary located outside India whose interim financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial results of these subsidiaries and an associate of a step down subsidiary, located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India (Indian Accounting Standards "Ind AS"). We have reviewed these conversion adjustments made by the Parent's Management.


- B. The Statement includes interim financial results of 5 subsidiaries incorporated outside India which have not been reviewed, whose interim financial results, reflect Group's share of total revenues (before consolidation adjustments) of Rs 323.48 Lakh, Group's share of total net loss after tax (before consolidation adjustments) of Rs. 463.33 Lakh and total comprehensive income (before consolidation adjustments) of Rs. (258.26) Lakh for the quarter ended June 30, 2025.

These interim financial results have been furnished to us by the Parent's Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on such interim financial results. According to the information and explanations given to us by the Management these interim financial results are not material to the Group.

- C. Attention is drawn to the fact that the figures for the quarter ended March 31, 2025, as reported in the Statement, are the balancing figures between the audited figures in respect of the full financial year ended March 31, 2025 and the published unaudited figures up to the end of the third quarter of the year ended March 31, 2025, which have been reviewed and not subjected to audit by us.

Our conclusion on the Statement is not modified in respect of the above matters.

For **Kalyaniwalla & Mistry LLP**  
Chartered Accountants  
Firm Registration No.: 104607W/W100166



Anil A. Kulkarni  
Partner  
Membership No.: 047576  
UDIN: 25047576BMKXLM6211  
Place: Mumbai  
Date: August 08, 2025



**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2025**

No.	PARTICULARS	(Rs.in Lakh, except per share data)							
		STANDALONE				CONSOLIDATED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025	30.06.2025	31.03.2025	30.06.2024	31.03.2025
	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	
1	Total Income from Operations	19,143.82	27,259.63	18,191.22	88,649.13	42,355.20	43,746.28	38,085.20	166,652.66
2	Net Profit / (Loss) for the period from continuing operations (before tax and exceptional items)	(1,637.65)	1,163.23	(1,759.69)	(2,742.84)	(426.42)	3,628.98	(705.15)	5,928.62
3	Net Profit / (Loss) for the period before tax from continuing operations (after exceptional items)	(1,637.65)	1,189.68	(1,759.69)	(12,343.05)	(426.42)	3,069.58	(705.15)	4,947.10
4	Total Net Profit / (Loss) for the period after tax (after exceptional items)	(1,068.10)	1,561.84	(1,368.01)	(7,631.05)	(1,068.11)	11.00	(3,465.02)	(15,811.94)
5	Net Profit / Loss for the period after tax and non-controlling interests (after exceptional items)					(996.07)	(72.40)	(3,395.41)	(13,904.59)
6	Total Comprehensive Income for the period	(1,045.63)	1,756.15	(1,312.71)	(7,685.09)	124.75	590.47	(4,059.89)	(17,035.43)
7	Equity Share Capital	1,879.21	1,879.21	1,674.95	1,879.21	1,879.21	1,879.21	1,674.95	1,879.21
8	Other Equity				84,347.71				88,288.09
9	Earnings per share (of Re 1/-each) (not annualised)								
	-Basic Rs.	(0.57)	0.86	(0.80)	(4.41)	(0.53)	(0.04)	(1.99)	(8.03)
	-Diluted Rs.	(0.56)	0.85	(0.80)	(4.36)	(0.52)	(0.04)	(1.98)	(8.03)

1 The above information is an extract of the detailed format of unaudited results for the quarter ended June 30, 2025 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited results for the quarter June 30, 2025 are available on the Company's website at [www.camlinfs.com](http://www.camlinfs.com) and the Stock Exchange websites i.e. [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com).

Place: Mumbai  
Date: August 8, 2025

For Camlin Fine Sciences Limited



Ashish S. Dandekar  
Chairman & Managing Director  
DIN: 01077379



Registered Office:

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLC075361

**Disclosure under Regulation 30 read with Schedule III of Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**

Particulars	Details		
	Mr. Joseph Conrad D'Souza (DIN: 00010576)	Mr. Hari Rajmohan (DIN: 11228394)	Mr. Santosh Parab (Chief Financial Officer)
<b>Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise</b>	Re-appointment as a Non-Executive Independent Director of the Company.	Appointment as an Alternate Director to Mr. Jens Van Nieuwenborgh (DIN: 07638244), Non-Executive Non-Independent Director of the Company.	The interim ad hoc charge of the Human Resources & Administration Department given to Mr. Santosh Parab, Chief Financial Officer of the Company pursuant to the resignation of Mr. Amarsinh Jadhavrao, Chief Executive (HR & Corporate Affairs), and until a suitable successor is appointed.
<b>Date of appointment/re-appointment/cessation (as applicable) &amp; term of appointment/re-appointment</b>	Re-appointed as a Non-Executive Independent Director of the Company, not liable to retire by rotation for a second term of five consecutive years for the period from September 29, 2025 to September 28, 2030 subject to the approval of the Shareholders of the Company.	Appointment as an Alternate Director to Mr. Jens Van Nieuwenborgh (DIN: 07638244), Non-Executive Non-Independent Director of the Company during the latter's absence on August 8, 2025.	With immediate effect until a suitable successor is appointed.
<b>Brief profile (in case of appointment)</b>	Mr. Joseph Conrad D'Souza holds a Master's Degree in Commerce and a Diploma in Financial Management from the University of Bombay, a Master's Degree in Business Administration from South Gujarat University, and is a Graduate of the Senior Executive Programme from the London Business School. He is a erstwhile Member of Executive Management and Chief Investor Relations Officer with HDFC Limited and is also on the Boards of Chalet Hotels Limited and Nations Trust Bank plc, Sri Lanka. He has extensive expertise across key areas including industry knowledge,	Mr. Hari Rajmohan joined Ackermans & van Haaren in September 2021 as Investment Manager and Head of the Singapore office. Previously, Mr. Rajmohan worked with Standard Chartered Bank in Singapore and Dubai. He is a seasoned private equity investor with 13 years' experience across mid-market family companies and VC-backed growth start-ups. Mr. Rajmohan is a graduate in Computer Engineering from Nanyang Technological University, Singapore.	Mr. Santosh Parab is a qualified Chartered Accountant with over two decades of experience in the auditing profession. He previously worked with B.K. Khare & Co, an Indian accounting firm. He has been associated with the Company for nine years, contributing his invaluable knowledge, expertise, and experience to the organization's continued success.


**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com

	understanding of government legislation and legislative processes, accounting and finance, law, marketing, risk management systems, strategic thinking from a governance perspective, compliance orientation, and his demonstrated integrity and high ethical standards.		
<b>disclosure of relationships between directors (in case of appointment of a director)</b>	Mr. Joseph Conrad D'Souza is not related to any of the Directors of the Company.	Mr. Hari Rajmohan is not related to any of the Directors of the Company.	Mr. Santosh Parab is not related to any of the Directors of the Company.
<b>Information as required pursuant to BSE Circular ref. no. LIST/COMP/14/2018-19 and NSE ref. no. NSFJMU2018/24, dated June 20 2018.</b>	Not debarred from holding the office of Director by virtue of order of SEBI or any other such authority.	Not debarred from holding the office of Director by virtue of order of SEBI or any other such authority.	Not Applicable



**Registered Office:**

Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.  
CIN: L74100MH1993PLCO75361



+91 22 6700 1000



+91 22 2832 4404



corporate@camlinfs.com



www.camlinfs.com